Related references
Note: Only part of the references are listed.Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized 13C magnetic resonance spectroscopy study
Desiree Abdurrachim et al.
DIABETES OBESITY & METABOLISM (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2018)
Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis
Milton Packer
DIABETES OBESITY & METABOLISM (2018)
SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Subodh Verma et al.
DIABETOLOGIA (2018)
EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY
Carlos G. Santos-Gallego et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes
W. Timothy Garvey et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2018)
Metabolic remodelling in heart failure
Edoardo Bertero et al.
NATURE REVIEWS CARDIOLOGY (2018)
Cardiac metabolism - A promising therapeutic target for heart failure
Hannah Noordali et al.
PHARMACOLOGY & THERAPEUTICS (2018)
Canagliflozin inhibits interleukin-1 beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms
Sarah J. Mancini et al.
SCIENTIFIC REPORTS (2018)
Dapagliflozin Attenuates Na+/H+ Exchanger-1 in Cardiofibroblasts via AMPK Activation
Yumei Ye et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments
Alvaro Garcia-Ropero et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Renal, metabolic and cardiovascular considerations of SGLT2 inhibition
Ralph A. DeFronzo et al.
NATURE REVIEWS NEPHROLOGY (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
Vaibhav B. Patel et al.
HEART FAILURE REVIEWS (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
Liang Xu et al.
EBIOMEDICINE (2017)
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure
Milton Packer
CIRCULATION (2017)
Diabetic db/db mice do not develop heart failure upon pressure overload: a longitudinal in vivo PET, MRI, and MRS study on cardiac metabolic, structural, and functional adaptations
Desiree Abdurrachim et al.
CARDIOVASCULAR RESEARCH (2017)
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D. Lopaschuk et al.
CELL METABOLISM (2016)
The Failing Heart Relies on Ketone Bodies as a Fuel
Gregory Aubert et al.
CIRCULATION (2016)
Diuretic Action of Sodium-Glucose Cotransporter 2 Inhibitors and Its Importance in the Management of Heart Failure
Genjiro Kimura
CIRCULATION JOURNAL (2016)
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
Ele Ferrannini et al.
DIABETES (2016)
The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
Simon A. Hawley et al.
DIABETES (2016)
Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis
Sunder Mudaliar et al.
DIABETES CARE (2016)
CV Protection in the EMPA-REG OUTCOME Trial: A Thrifty Substrate Hypothesis
Ele Ferrannini et al.
DIABETES CARE (2016)
Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis
F. Zaccardi et al.
DIABETES OBESITY & METABOLISM (2016)
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Piotr Ponikowski et al.
EUROPEAN HEART JOURNAL (2016)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
R. Chilton et al.
DIABETES OBESITY & METABOLISM (2015)
Safety and efficacy of canagliflozin in Japanese patients with type 2 diabetes mellitus: post hoc subgroup analyses according to body mass index in a 52-week open-label study
Nobuya Inagaki et al.
EXPERT OPINION ON PHARMACOTHERAPY (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
David Z. I. Cherney et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling
Rebecca C. Schugar et al.
MOLECULAR METABOLISM (2014)
Ketone body metabolism and cardiovascular disease
David G. Cotter et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2013)
Cardiac Metabolism in Heart Failure Implications Beyond ATP Production
Torsten Doenst et al.
CIRCULATION RESEARCH (2013)
Cardiac Metabolism and its Interactions With Contraction, Growth, and Survival of Cardiomyocytes
Stephen C. Kolwicz et al.
CIRCULATION RESEARCH (2013)
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani et al.
DIABETES (2013)
Loss of NHE1 activity leads to reduced oxidative stress in heart and mitigates high-fat diet-induced myocardial stress
Vikram Prasad et al.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY (2013)
Cardiac-Specific Deletion of Acetyl CoA Carboxylase 2 Prevents Metabolic Remodeling During Pressure-Overload Hypertrophy
Stephen C. Kolwicz et al.
CIRCULATION RESEARCH (2012)
Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Chronic inhibition of the Na+/H+-exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodelling
A. Baartscheer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity
J Buchanan et al.
ENDOCRINOLOGY (2005)
Myocardial substrate metabolism in the normal and failing heart
WC Stanley et al.
PHYSIOLOGICAL REVIEWS (2005)
Profiling substrate fluxes in the isolated working mouse heart using 13C-labeled substrates:: focusing on the origin and fate of pyruvate and citrate carbons
M Khairallah et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2004)
The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism
RL Veech
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2004)
Cardiac abnormalities in diabetic patients with neuropathy - Effects of aldose reductase inhibitor administration
BF Johnson et al.
DIABETES CARE (2004)
Is the failing heart energy starved? On using chemical energy to support cardiac function
JS Ingwall et al.
CIRCULATION RESEARCH (2004)
Acidosis downregulates leptin production from cultured adipocytes through a glucose transport-dependent post-transcriptional mechanism
D Teta et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2003)
Differential modulation of glucose, lactate, and pyruvate oxidation by insulin and dichloroacetate in the rat heart
S Lloyd et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with 31P-SLOOP magnetic resonance spectroscopy
M Beer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
Adaptation and maladaptation of the heart in diabetes: Part I General concepts
H Taegtmeyer et al.
CIRCULATION (2002)
The effect of leptin on Na+-H+ antiport (NHE 1) activity of obese and normal subjects erythrocytes
A Konstantinou-Tegou et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2001)
Cardiac complications in pediatric patients on the ketogenic diet
TH Best et al.
NEUROLOGY (2000)
Lipotoxic heart disease in obese rats: Implications for human obesity
YT Zhou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Cardiac fatty acid uptake and transport in health and disease
GJ van der Vusse et al.
CARDIOVASCULAR RESEARCH (2000)
Share Paper
